College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, China.
Medicine (Baltimore). 2021 Mar 5;100(9):e24587. doi: 10.1097/MD.0000000000024587.
Assessing the effectiveness and safety of traditional Chinese medicine on liver fibrosis is the main purpose of this systematic review protocol.
The following electronic databases will be searched from their respective inception dates to 1st December 2021: PubMed, MEDLINE, the Cochrane Library, Embase, WorldSciNet, Ovid, the Allied and Complementary Medicine Database, the Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, the Chongqing VIP Chinese Science and Technology Periodical Database, the Wanfang Database, and the China Biology Medicine Disc. All published randomized controlled trials in English or Chinese related to curative effects of Traditional Chinese medicine on liver fibrosis will be included. The primary outcome is the levels of serum hyaluronic acid, laminin, type III procollagen, and type IV procollagen. There is no secondary outcomes. Two reviewers will conduct the study selection, data extraction, and assessment independently. The assessment of risk of bias and data synthesis will be conducted with Review Manager Software V.5.2.
The results will provide a high-quality synthesis of current evidence for researchers in this subject area.
The conclusion of our study will provide an evidence to judge whether traditional Chinese medicine is an effective intervention for patients with liver fibrosis.
INPLASY202110017.
本系统评价旨在评估中药抗肝纤维化的有效性和安全性。
我们将从各数据库建库起至 2021 年 12 月 1 日，检索以下电子数据库：PubMed、MEDLINE、Cochrane 图书馆、Embase、WorldSciNet、Ovid、辅助与补充医学数据库、Web of Science、中国生物医学文献数据库、中国知网、重庆维普中文科技期刊数据库、万方数据库和中国生物医学文献数据库。纳入所有发表的、英文或中文的关于中药抗肝纤维化疗效的随机对照试验。主要结局指标是血清透明质酸、层粘连蛋白、III 型前胶原和 IV 型前胶原的水平。无次要结局指标。两名评审员将独立进行研究选择、数据提取和评估。将使用 Review Manager Software V.5.2 进行偏倚风险评估和数据合成。
研究结果将为该领域的研究人员提供高质量的综合现有证据。
本研究的结论将为判断中药是否是肝纤维化患者的有效干预措施提供依据。
INPLASY202110017。
Zotero 插件